Xiamen Amoytop Biotech (688278.SH) signed a cooperation agreement with Tengji Pharmaceutical on NM6606 technology licensing and development.

Xiamen Amoytop Biotech (688278.SH) announced that the company signed a Technology License and Development Cooperation Agreement with Tengji (Xiamen) Biomedical Technology Co., Ltd. (referred to as "Tengji Medicine") on September 20, 2024. According to the agreement, the company obtained the paid license to develop, register, and commercialize a monotherapy product containing the licensed compound for the treatment of liver fat metabolism and liver fibrosis-related diseases in China (including mainland China, Hong Kong, Macau, and Taiwan) along with related intellectual property rights. The company will pay Tengji Medicine an initial payment of 10 million RMB and up to a maximum of 135 million RMB for development and sales milestone payments, as well as an annual royalty fee based on a certain percentage of net sales after the agreement becomes effective. NM6606, developed by Tengji Medicine, is a "First-in-Class" oral drug targeting retinoic acid X receptor (RXR) intended to treat non-alcoholic steatohepatitis (NASH). In March 2024, it was approved by the National Medical Products Administration for clinical trials in China, with the clinical trial application acceptance numbers of CXHL2301424 (20mg) and CXHL2301425 (100mg). This collaboration aligns with the company's overall development strategy, further enriching its pipeline in the prevention and treatment of liver diseases and providing more treatment options for unmet clinical needs.